| Shi, Ming |
| Completed | 3 | 214 | RoW | Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen, HAIC Regimen, Oral Sorafenib | Sun Yat-sen University | Hepatocellular Carcinoma | 10/20 | 07/24 | | |
NCT04667351: HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial |
|
|
| Recruiting | 3 | 400 | RoW | 2400 mg/m² 5-fu, 1200 mg/m² 5-fu | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | HepatoCellular Carcinoma | 12/22 | 12/22 | | |
NCT04687163: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial |
|
|
| Recruiting | 3 | 400 | RoW | HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital | Hepatocellular Carcinoma | 12/22 | 12/22 | | |
NCT03469479: Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria |
|
|
| Recruiting | 3 | 252 | RoW | FOLFOX, Hepatic Arterial Infusion Chemotherapy of FOLFOX, Hepatic resection | Sun Yat-sen University | Hepatocellular Carcinoma | 03/23 | 03/23 | | |
NCT03780049: HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B |
|
|
| Recruiting | 3 | 304 | RoW | HAIC of FOLFOX, Hepatic artery infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin, H101, Recombinant Human Type-5 Adenovirus, Placebos, normal saline | Sun Yat-sen University | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial |
|
|
| Recruiting | 3 | 200 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin | Sun Yat-sen University | Hepatocellular Carcinoma | 07/25 | 12/26 | | |
NCT05866172: HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC |
|
|
| Recruiting | 3 | 264 | RoW | HAIC, Zoledronic acid | Sun Yat-sen University | Hepatocellular Carcinoma | 12/24 | 06/25 | | |
NCT05476432: HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study |
|
|
| Recruiting | 3 | 300 | RoW | HAIC, FOLFOX 2d, FOLFOX 1d | Sun Yat-sen University, Guangzhou No.12 People's Hospital, First People's Hospital of Foshan | Hepatocellular Carcinoma | 07/25 | 10/26 | | |
NCT04961970: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC |
|
|
| Recruiting | 3 | 188 | RoW | oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin | Shi Ming | Intrahepatic Cholangiocarcinoma | 07/25 | 07/25 | | |
NCT05198609: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial |
|
|
| Recruiting | 3 | 214 | RoW | FOLFOX-HAIC, Camrelizumab, Apatinib | Sun Yat-sen University | Hepatocellular Carcinoma | 01/26 | 01/26 | | |
NCT03722498: Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE |
|
|
| Withdrawn | 2 | 100 | RoW | HAIC of FOLFOX, Oxaliplatin , fluorouracil, and leucovorin, Sorafenib | Sun Yat-sen University, Guangzhou No.12 People's Hospital, Kaiping Central Hospital | Hepatocellular Carcinoma | 03/21 | 03/21 | | |
NCT04170179: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Systemic chemotherapy, Lenvatinib, Toripalimab | Sun Yat-sen University | Hepatocellular Carcinoma | 04/21 | 04/21 | | |
NCT04769908: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis |
|
|
| Recruiting | 2 | 40 | RoW | Systemic Chemotherapy, Lenvatinib, Sintilimab | Sun Yat-sen University | ICC | 12/21 | 12/21 | | |
NCT03945487: Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis |
|
|
| Recruiting | 2 | 200 | RoW | umbilical cord-derived mesenchymal stem cell, Comprehensive treatment | Beijing 302 Hospital | Decompensated Liver Cirrhosis | 12/21 | 12/23 | | |
NCT04317248: "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 600 | RoW | Cyclophosphamide, Endoxan, Multiple Signals loaded Dendritic Cells Vaccine, MSDCV | Yuehua Huang, Sun Yat-sen University, Nanfang Hospital of Southern Medical University | Hepatocellular Carcinoma | 04/22 | 04/22 | | |
NCT04135690: HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial |
|
|
| Recruiting | 2 | 60 | RoW | Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib, systemic treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T |
|
|
| Recruiting | 2 | 30 | RoW | Candonilimab, Bevacizumab | Shi Ming | Hepatocellular Carcinoma | 01/24 | 07/24 | | |
NCT05886465: HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial |
|
|
| Recruiting | 2 | 40 | RoW | Atezolizumab, Bevacizumab, HAIC with FOLFOX | Sun Yat-sen University | Hepatocellular Carcinoma | 06/24 | 12/24 | | |
NCT05985863: Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure |
|
|
| Recruiting | 1/2 | 150 | RoW | standard medical treatment, Placebo, hUC-MSC, hUC-MSC_Prolonged | Beijing 302 Hospital, Shulan (Hang Zhou) Hospital, BeijingYouan Hospital, Shenzhen Third People's Hospital, Shen Zhen Wingor Biotechnology CO. LTD | Acute-On-Chronic Liver Failure | 12/26 | 12/28 | | |
NCT04715321: CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 120 | RoW | CT perfusion examination | Sun Yat-sen University | Hepatocellular Carcinoma | 12/21 | 12/21 | | |
NCT04680598: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study |
|
|
| Recruiting | N/A | 800 | RoW | ICI, Antiviral Prophylaxis | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital, ZhongShan People 's Hospital | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
